186 related articles for article (PubMed ID: 32857613)
1. The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma.
Grisanti S; Cosentini D; Laganà M; Volta AD; Palumbo C; Massimo Tiberio GA; Sigala S; Berruti A
Future Oncol; 2020 Dec; 16(36):3017-3020. PubMed ID: 32857613
[No Abstract] [Full Text] [Related]
2. Adrenocortical Carcinoma Steroid Profiles:
Muzzi JCD; Magno JM; Cardoso MA; de Moura J; Castro MAA; Figueiredo BC
Front Endocrinol (Lausanne); 2021; 12():672319. PubMed ID: 34194394
[TBL] [Abstract][Full Text] [Related]
3. The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature.
Brabo EP; Moraes AB; Neto LV
J Endocrinol Invest; 2020 Nov; 43(11):1531-1542. PubMed ID: 32468513
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
6. Identification of immune-related biomarkers in adrenocortical carcinoma: Immune-related biomarkers for ACC.
Peng Y; Song Y; Ding J; Li N; Zhang Z; Wang H
Int Immunopharmacol; 2020 Nov; 88():106930. PubMed ID: 32919215
[TBL] [Abstract][Full Text] [Related]
7. Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma.
Xu F; Guan Y; Zhang P; Xue L; Ma Y; Gao M; Chong T; Ren BC
BMC Endocr Disord; 2022 May; 22(1):130. PubMed ID: 35568842
[TBL] [Abstract][Full Text] [Related]
8. Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma.
Tierney JF; Vogle A; Finnerty B; Zarnegar R; Ghai R; Gattuso P; Fahey TJ; Keutgen XM
J Surg Res; 2020 Dec; 256():90-95. PubMed ID: 32683062
[TBL] [Abstract][Full Text] [Related]
9. Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment.
Baechle JJ; Hanna DN; Sekhar KR; Rathmell JC; Rathmell WK; Baregamian N
Surgery; 2022 Jan; 171(1):111-118. PubMed ID: 34261605
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for the treatment of adrenocortical carcinoma.
Sukrithan V; Husain M; Kirschner L; Shah MH; Konda B
Expert Opin Emerg Drugs; 2021 Jun; 26(2):165-178. PubMed ID: 33896321
[No Abstract] [Full Text] [Related]
11. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.
Lang J; Capasso A; Jordan KR; French JD; Kar A; Bagby SM; Barbee J; Yacob BW; Head LS; Tompkins KD; Freed BM; Somerset H; Clark TJ; Pitts TM; Messersmith WA; Eckhardt SG; Wierman ME; Leong S; Kiseljak-Vassiliades K
J Clin Endocrinol Metab; 2020 Jan; 105(1):26-42. PubMed ID: 31513709
[TBL] [Abstract][Full Text] [Related]
12. Management of Adrenocortical Carcinoma.
Jasim S; Habra MA
Curr Oncol Rep; 2019 Feb; 21(3):20. PubMed ID: 30798468
[TBL] [Abstract][Full Text] [Related]
13. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma.
Landwehr LS; Altieri B; Schreiner J; Sbiera I; Weigand I; Kroiss M; Fassnacht M; Sbiera S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32474412
[TBL] [Abstract][Full Text] [Related]
14. Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours.
Dos Santos Passaia B; Lima K; Kremer JL; da Conceição BB; de Paula Mariani BM; da Silva JCL; Zerbini MCN; Fragoso MCBV; Machado-Neto JA; Lotfi CFP
Invest New Drugs; 2020 Jun; 38(3):899-908. PubMed ID: 31441020
[TBL] [Abstract][Full Text] [Related]
15. Adrenocortical carcinoma in children: a role for etoposide and cisplatin adjuvant therapy? Preliminary report.
Hovi L; Wikström S; Vettenranta K; Heikkilä P; Saarinen-Pihkala UM
Med Pediatr Oncol; 2003 May; 40(5):324-6. PubMed ID: 12652623
[No Abstract] [Full Text] [Related]
16. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
[TBL] [Abstract][Full Text] [Related]
17. 5th International ACC Symposium: An Outlook to Current and Future Research on the Biology of Adrenocortical Carcinoma: Diagnostic and Therapeutic Applications.
Lalli E; Sasano H
Horm Cancer; 2016 Feb; 7(1):44-8. PubMed ID: 26666256
[TBL] [Abstract][Full Text] [Related]
18. Current Prospects for Adrenocortical Carcinoma Pharmacotherapy.
Ławnicka H
Recent Pat Anticancer Drug Discov; 2023; 18(1):29-37. PubMed ID: 36482727
[TBL] [Abstract][Full Text] [Related]
19. Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma.
Pak C; Yoon S; Lee JL; Yun T; Park I
Curr Oncol Rep; 2024 Apr; 26(4):307-317. PubMed ID: 38381366
[TBL] [Abstract][Full Text] [Related]
20. Molecular markers and targeted therapies for adrenocortical carcinoma.
Xu Y; Qi Y; Zhu Y; Ning G; Huang Y
Clin Endocrinol (Oxf); 2014 Feb; 80(2):159-68. PubMed ID: 24304415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]